CLL1 expression in AML patient blasts and comparison of percent positivity in the CD33 and CLL1 expression in LSCs
| AML subtype . | Positive CLL1 expression in AML patient blast cells* . | CLL1 and CD33 expression and percent positivity in LSCs . | ||
|---|---|---|---|---|
| CD33 . | CLL1 . | |||
| FAB subtype† | M1 | 22/22 | 10/11 | 10/11 |
| M2 | 20/22 | 5/8 | 7/8 | |
| M4 | 17/18 | 2/6 | 6/6 | |
| M5 | 12/13 | 3/4 | 4/4 | |
| Others | 3/8 | |||
| N/A | 6/7 | 0/2 | 0/2 | |
| Cytogenetic risk categories‡ | Poor§ | 29/34 | 3/7 | 7/7 |
| Intermediate|| | 33/34 | 11/14 | 12/14 | |
| Favorable¶ | 15/15 | 4/7 | 6/7 | |
| N/A | 4/7 | 2/3 | 2/3 | |
| Bone marrow | 8/8 | |||
| Peripheral blood | 73/82 | |||
| Total | 81/90 (90%) | 20/31 | 27/31 | |
| AML subtype . | Positive CLL1 expression in AML patient blast cells* . | CLL1 and CD33 expression and percent positivity in LSCs . | ||
|---|---|---|---|---|
| CD33 . | CLL1 . | |||
| FAB subtype† | M1 | 22/22 | 10/11 | 10/11 |
| M2 | 20/22 | 5/8 | 7/8 | |
| M4 | 17/18 | 2/6 | 6/6 | |
| M5 | 12/13 | 3/4 | 4/4 | |
| Others | 3/8 | |||
| N/A | 6/7 | 0/2 | 0/2 | |
| Cytogenetic risk categories‡ | Poor§ | 29/34 | 3/7 | 7/7 |
| Intermediate|| | 33/34 | 11/14 | 12/14 | |
| Favorable¶ | 15/15 | 4/7 | 6/7 | |
| N/A | 4/7 | 2/3 | 2/3 | |
| Bone marrow | 8/8 | |||
| Peripheral blood | 73/82 | |||
| Total | 81/90 (90%) | 20/31 | 27/31 | |
N/A, not defined.
AML blast population with >30% positive for CLL1 staining in FACS analysis was considered to be a CLL1+. The mean value for the percentage of CLL1+ in AML blast is 49.9% ± 0.3%. Contaminating nonneoplastic cells were removed by gating the AML blast population using CD45 and side scatter properties. Blasts typically show dim CD45 expression and low side scatter properties, which allows easy separation from lymphocytes, granulocytes, and monocytes.
AML patient samples were subcategorized according to FAB subtype. “Others” category is patient samples classified as M0, M6, or CML blast crisis (N = 2). “N/A” category is patient samples that were unable to be subcategorized into FAB subtypes due to lack of pathological information.
Cytogenetic risk categories were defined following guidelines of “National Comprehensive Cancer Network” version 2.2014 Acute Myeloid Leukemia.
Poor: Complex (3 or more chromosomal abnormalities); Monosomal karyotype −5, 5q−, −7, 7q-11q23 - non t(9;11)inv(3), t(3;3) t(6;9) t(9;22).
Intermediate: Normal cytogenetics + 8 (isolated) t(9;11).
Favorable: inv(16) or t(16;16) t(8;21) t(15;17).